Developing Systemic Therapy for Esophagogastric Cancer

Video
Conference|ASCO Annual Meeting: Gastrointestinal Cancer

Cancer Network spoke with Dr. Karyn Goodman about the importance of developing a systematic therapy regimen for the treatment of esophagogastric cancer.

Cancer Network spoke with Dr. Karyn Goodman about the importance of developing a systematic therapy regimen for the treatment of esophagogastric cancer.

Recent Videos
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Tanio S. Bekaii-Saab, MD, on Potential of Dual Targeting to Transform Treatment of HER2+ CRC
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Kyle Doherty
Published: June 2nd 2024 | Updated: June 3rd 2024
Article

The combination of perioperative chemotherapy plus FLOT improved overall survival vs neoadjuvant chemoradiation in patients with resectable esophageal cancer.

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Geoffrey Y. Ku, MD
January 18th 2017
Podcast

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Trimodality Therapy Leads to QOL Improvement in Esophageal Cancer

Trimodality Therapy Leads to QOL Improvement in Esophageal Cancer

Ariana Pelosci
January 24th 2024
Article

Investigators note that early interventions such as nutritional support and prehabilitation require further investigation to increase both the quality of life and overall survival for patients with esophageal cancer.

Evidence Moves OTC Prevention of mCRC Closer to Reality

Evidence Moves OTC Prevention of mCRC Closer to Reality

Andrew T. Chan, MD, MPH
May 27th 2015
Podcast

Ahead of the 2015 ASCO Annual Meeting, we are discussing over-the-counter therapies for patients with metastatic colorectal cancer with Andrew T. Chan, MD, MPH.

Neoadjuvant camrelizumab plus chemotherapy may hold promise as a standard of care in locally advanced esophageal squamous cell carcinoma, according to Yin Li, MD.

Camrelizumab/Chemo Improves pCRs Vs Chemo in Locally Advanced ESCC

Gina Mauro
January 19th 2024
Article

Neoadjuvant camrelizumab plus chemotherapy may hold promise as a standard of care in locally advanced esophageal squamous cell carcinoma, according to Yin Li, MD.

Sugemalimab is now approved for managing esophageal squamous cell carcinoma in China following results from the phase 3 GEMSTONE-304 study.

Sugemalimab Earns Chinese Approval for Esophageal Squamous Cell Carcinoma

Hayley Virgil
January 3rd 2024
Article

Sugemalimab is now approved for managing esophageal squamous cell carcinoma in China following results from the phase 3 GEMSTONE-304 study.